Merck, 196000-1SET, Bafilomycin A1, Streptomyces griseus

General description
A macrolide antibiotic that acts as a specific inhibitor of vacuolar-type H⁺-ATPase (V-type; Ki = 500 pM). A valuable tool for distinguishing among different types of ATPases. Blocks lysosomal cholesterol trafficking in macrophages and is known to interfere with pH regulation in brain cells. Exhibits cytotoxic effects on a number of cell lines in a cell viability assay. Reported to selectively inhibit β-secretase, an enzyme involved in the processing of amyloid precursor protein (APP).
Note: 1 set = 3 x 10 µg
Biochem/physiol Actions
Primary Target
vacuolar type H⁺ ATPase
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). DMSO stock solutions are stable for up to 1 year at -20°C.
Other Notes
Sinha, S., and Lieberburg, I. 1999. Proc. Natl. Acad. Sci. USA96, 11049.
Calvert, C.M., and Sanders, D. 1995. J. Biol. Chem.270, 7272.
Nishihara, T., et al. 1995. Biochem. Biophys. Res. Commun.269, 255.
Crider, B.P., et al. 1994. J. Biol. Chem.269, 17379.
Palokangas, H., et al. 1994. J. Biol. Chem.269, 17577.
Sundquist, K.T., and Marks, S.C., Jr. 1994. J. Bone Miner. Res.9, 1575.
Drose, S., et al. 1993. Biochemistry32, 3902.
Furuchi, T., et al. 1993. J. Biol. Chem.268, 27345.
Bowman, E.J., et al. 1988. Proc. Natl. Acad. Sci. USA85, 7972.
Disclaimer
Toxicity: Carcinogenic / Teratogenic (D)